14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AHCO vs IART: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IART carries 45.5/100 (HOLD) at $13.25 (5.6x Forward P/E, 9.9% operating margin).
Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IART is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $1.1B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment45.6% of Rev ($755M)
90D Engineering Disclosures0 Published
Investor FAQ AHCO vs IART Key Questions & Quantitative Answers
As of Nov 20, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas IART carries 45.5/100 (HOLD) at $13.25 (5.6x Forward P/E, 9.9% operating margin). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile IART is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AHCO leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with IART at +2.3% YoY revenue growth and +0.4% YoY earnings growth on $1.66B TTM revenue (55.5% gross margin, 9.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while IART shifted +11.6%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 45.6% of Rev ($755M) (0 disclosures) for IART.
IART screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas IART trades at 5.6x Forward P/E, 79.7x Trailing P/E, 0.71x PEG, and 0.6x EV/Revenue (4.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus IART (1.2% ROE) capital efficiency.
In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, IART carries 57.4% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.54β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.